A San Francisco-based startup is inching closer to FDA approval for its drug that promises to extend the lifespan of large dogs.
The longevity industry isn’t just looking at humans: A drug that could extend the lifespans of large dogs inches closer to FDA approval, anticipated to be available in 2026.
Details: Loyal for Dogs — a San Francisco-based biotech company — revealed that the drug it’s developing, LOY-001, has cleared one of the FDA’s hurdles required for their Expanded Conditional Approval.
Yes, but: While Loyal’s drug works by reducing IGF-1 levels to improve the lifespan of large dogs, another study published last month reported another possible culprit — a gene called ERBB4.
A dog’s size and its expected lifespan have an inverse relationship: Their lives seem to pan out in “fast motion,” succumbing to age-related illnesses and cancer earlier in life, according to the American Kennel Club.
Watch out: Loyal’s experimental drug is an injection meant to be given every three to six months by a veterinarian, noted Wired, but the company is also developing two other drugs: a pill version for large breeds, and a pill for older dogs of all breeds.
This is also the first time the FDA has indicated some willingness to endorse a longevity drug, which will likely have some implications for similar drugs targeting humans.